Tirzepatide vs. Semaglutide: Comparing New Weight Loss Drugs

• Tirzepatide (Mounjaro) and Semaglutide (Wegovy) are highly effective, next-generation weight loss medications.
• Tirzepatide, a dual GIP and GLP-1 agonist, generally shows higher average weight loss than Semaglutide, a GLP-1 agonist.
• Both medications are administered via weekly injections and require a doctor's prescription.
• Hi Doctor AI offers convenient online consultations with EU-licensed doctors for these and other weight management treatments.

Weight management has seen significant advancements with the introduction of new medications that offer substantial weight loss results. Among the most discussed are Tirzepatide (marketed as Mounjaro) and Semaglutide (marketed as Wegovy). Both are powerful tools in the fight against obesity, but they have distinct mechanisms and efficacy profiles. Understanding these differences can help you and your doctor determine the best path forward.

Understanding GLP-1 and GIP Agonists

Before diving into the specifics of each drug, it's important to understand the class of medications they belong to. Both Tirzepatide and Semaglutide are incretin mimetics, meaning they mimic the effects of natural hormones in your body that regulate blood sugar and appetite.

• GLP-1 (Glucagon-like Peptide-1) Agonists: Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone that plays a crucial role in glucose metabolism. It stimulates insulin release, suppresses glucagon secretion, slows gastric emptying, and reduces appetite by acting on the brain's satiety centers. This combination leads to improved blood sugar control and significant weight loss.
• GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 Agonists: Tirzepatide is unique as it is a dual agonist, targeting both GLP-1 and GIP receptors. GIP is another incretin hormone that works synergistically with GLP-1 to enhance insulin secretion and improve metabolic function. By activating both pathways, Tirzepatide offers a more comprehensive approach to blood sugar regulation and weight reduction.

Efficacy and Expected Weight Loss

When comparing weight loss efficacy, clinical trials provide the most reliable data:

• Semaglutide (Wegovy): In the STEP (Semaglutide Treatment Effect in People with Obesity) trials, participants receiving Semaglutide achieved an average weight loss of approximately 15-17% of their initial body weight over 68 weeks. This represents a significant and clinically meaningful reduction in weight, far surpassing older generations of weight loss medications.

• Tirzepatide (Mounjaro): The SURMOUNT clinical trials for Tirzepatide showed even more impressive results. Participants on the highest dose of Tirzepatide achieved an average weight loss of up to 22.5% of their initial body weight over 72 weeks. This makes Tirzepatide one of the most effective pharmacological treatments for obesity currently available.

It's important to note that individual results may vary, and these medications are most effective when combined with lifestyle changes, including a balanced diet and regular physical activity.

Administration and Dosage

Both medications are administered via a once-weekly subcutaneous injection. They come in pre-filled pens, making self-administration relatively straightforward after proper training from a healthcare professional.

• Semaglutide (Wegovy): The dosage typically starts low (0.25mg) and is gradually increased over several weeks to a maintenance dose (up to 2.4mg) to minimize gastrointestinal side effects. This titration schedule allows the body to adjust to the medication.

• Tirzepatide (Mounjaro): Similar to Semaglutide, Tirzepatide also involves a dose escalation schedule, starting at 2.5mg and increasing incrementally to a maximum of 15mg once weekly. The gradual increase helps manage potential side effects.

Your doctor will determine the appropriate starting dose and titration schedule based on your individual needs and tolerance.

Potential Side Effects

As with any medication, Tirzepatide and Semaglutide can cause side effects. The most common side effects for both drugs are gastrointestinal in nature:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain

These side effects are often mild to moderate and tend to decrease over time as your body adjusts to the medication. The gradual dose escalation is designed to mitigate these effects. Less common but more serious side effects can include pancreatitis, gallbladder problems, and thyroid C-cell tumors (seen in animal studies, but not confirmed in humans for GLP-1 agonists).

It is crucial to discuss your full medical history with an EU-licensed doctor to ensure these medications are safe and appropriate for you.

Cost and Accessibility through Hi Doctor AI

The cost of these medications can be a significant factor for many individuals. While Hi Doctor AI does not sell or ship medications, we facilitate access to prescriptions from EU-licensed doctors. The consultation fee for weight loss treatments with Hi Doctor AI is 45€.

This allows you to receive a valid prescription that can be used at any licensed pharmacy across the EU. This approach offers a convenient and discreet way to explore treatment options for weight management from the comfort of your home, without the need for a video call.

Hi Doctor AI provides telemedicine consultations. All treatments are prescribed by EU-licensed doctors after reviewing your medical history. We do not sell or ship medications—prescriptions can be used at any licensed pharmacy in the EU.

Ready to start your weight loss journey? Get your online consultation with Hi Doctor AI—EU-licensed doctors, 45€ consultation fee.